公开(公告)号：US11767303B2

公开(公告)日：2023-09-26

申请号：US17384051

申请日：2021-07-23

申请人： Health Research, Inc. ,  Arizona Board of Regents on Behalf of the University of Arizona ,  Board of Regents, The University of Texas System

发明人： Hongmin Li ,  Zhong Li ,  Jia Zhou ,  Jimin Xu ,  Qing-Yu Zhang

IPC分类号： A61K31/5375 ,  C07D265/30 ,  C07C233/75 ,  C07D211/46 ,  A61P31/14 ,  C07D409/12 ,  C07D213/75 ,  C07D333/54

CPC分类号： C07D265/30 ,  A61P31/14 ,  C07C233/75 ,  C07D211/46 ,  C07D213/75 ,  C07D333/54 ,  C07D409/12

摘要： The present disclosure relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof. The present disclosure further relates to methods of inhibiting viral replication including contacting one or more cells that have been infected with a virus with an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein the virus comprises a flavivirus. Also disclosed is a method of treating and/or preventing a flavivirus infection and/or a condition resulting from a flavivirus infection including administering an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof under conditions effective to treat and/or prevent a flavivirus infection and/or a condition resulting from a flavivirus infection.

公开(公告)号：US09884863B2

公开(公告)日：2018-02-06

申请号：US15380798

申请日：2016-12-15

申请人： Board of Regents, The University of Texas System

发明人： Jia Zhou ,  Haijun Chen ,  Qiang Shen

IPC分类号： C07D471/04 ,  C07D409/12 ,  C07D333/64

CPC分类号： C07D471/04 ,  A61K9/0019 ,  A61K31/166 ,  A61K31/167 ,  A61K31/18 ,  A61K31/222 ,  A61K31/381 ,  A61K31/4245 ,  A61K31/4436 ,  A61K31/4465 ,  A61K31/4535 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/473 ,  A61K31/495 ,  A61K31/496 ,  A61K31/5375 ,  A61K31/5377 ,  A61K45/06 ,  C07C235/60 ,  C07C235/64 ,  C07C311/08 ,  C07D211/40 ,  C07D211/46 ,  C07D215/52 ,  C07D265/30 ,  C07D295/155 ,  C07D295/24 ,  C07D333/54 ,  C07D333/64 ,  C07D409/12 ,  C07D413/04 ,  A61K2300/00

摘要： Provided are STAT3 inhibitors and methods of treating inflammation or a hyperproliferative disease such as, e.g., cancer. In some aspects, compounds may be used to treat breast cancer, a head/neck cancer, a lung cancer, a prostate cancer, or pancreatic cancer.

公开(公告)号：US20240325383A1

公开(公告)日：2024-10-03

申请号：US18613203

申请日：2024-03-22

申请人： Board of Regents, The University of Texas System

发明人： Alexander Bukreyev ,  Jia Zhou

IPC分类号： A61K31/496 ,  A61K31/573 ,  A61K31/675 ,  A61K45/06 ,  A61P11/02

CPC分类号： A61K31/496 ,  A61K31/573 ,  A61K31/675 ,  A61K45/06 ,  A61P11/02

摘要： Embodiments are directed to molecules for the treatment of Coronavirus infection, including SARS-COV-2 infection. In certain aspects the small molecule is administered via inhalation and/or intranasal administration.

公开(公告)号：US11773065B2

公开(公告)日：2023-10-03

申请号：US17499299

申请日：2021-10-12

申请人： Board of Regents, The University of Texas System

发明人： Jia Zhou ,  John A. Allen ,  Pingyuan Wang ,  Daniel E. Felsing

IPC分类号： C07D213/74 ,  C07D405/12 ,  C07D403/14 ,  C07D401/04 ,  C07D403/04 ,  C07D401/12

CPC分类号： C07D213/74 ,  C07D401/04 ,  C07D401/12 ,  C07D403/04 ,  C07D403/14 ,  C07D405/12

摘要： Embodiments are directed to novel GPR52 activators. In particular, a series of novel 1-(pyrimidin-4-yl)indoline-4-carboxamide analogs that have been identified as potent and selective GPR52 agonists. The optimized GPR52 agonist that, for example, can be used as a valuable pharmacological tool or a drug candidate for investigating the physiological and therapeutic potential of GPR52 activation for various human diseases.

公开(公告)号：US09562002B2

公开(公告)日：2017-02-07

申请号：US14760711

申请日：2014-01-15

申请人： Board of Regents, The University of Texas System

发明人： Jia Zhou ,  Haijun Chen ,  Qiang Shen

IPC分类号： C07C235/64 ,  C07D265/30 ,  C07D211/40 ,  A61K45/06 ,  A61K31/167 ,  A61K31/222 ,  A61K31/381 ,  A61K31/4436 ,  A61K31/4465 ,  A61K31/4535 ,  A61K31/4709 ,  A61K31/473 ,  A61K31/495 ,  A61K31/496 ,  A61K31/5377 ,  A61K9/00 ,  A61K31/166 ,  A61K31/18 ,  A61K31/4245 ,  A61K31/47 ,  A61K31/5375 ,  C07C235/60 ,  C07C311/08 ,  C07D211/46 ,  C07D215/52 ,  C07D295/155 ,  C07D295/24 ,  C07D333/54 ,  C07D333/64 ,  C07D409/12 ,  C07D413/04

CPC分类号： C07D471/04 ,  A61K9/0019 ,  A61K31/166 ,  A61K31/167 ,  A61K31/18 ,  A61K31/222 ,  A61K31/381 ,  A61K31/4245 ,  A61K31/4436 ,  A61K31/4465 ,  A61K31/4535 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/473 ,  A61K31/495 ,  A61K31/496 ,  A61K31/5375 ,  A61K31/5377 ,  A61K45/06 ,  C07C235/60 ,  C07C235/64 ,  C07C311/08 ,  C07D211/40 ,  C07D211/46 ,  C07D215/52 ,  C07D265/30 ,  C07D295/155 ,  C07D295/24 ,  C07D333/54 ,  C07D333/64 ,  C07D409/12 ,  C07D413/04 ,  A61K2300/00

摘要： Provided are STAT3 inhibitors and methods of treating inflammation or a hyperproliferative disease such as, e.g., cancer. In some aspects, compounds may be used to treat breast cancer, a head/neck cancer, a lung cancer, a prostate cancer, or pancreatic cancer.

摘要翻译： 提供了STAT3抑制剂和治疗炎症或过度增殖性疾病例如癌症的方法。 在一些方面，化合物可用于治疗乳腺癌，头颈癌，肺癌，前列腺癌或胰腺癌。